{
  "prompt": {
    "guidelineId": "carbetocin-to-prevent-pph-at-cs-uhs-cg-0009-2023-pdf",
    "fieldsProcessed": [
      "humanFriendlyName",
      "organisation",
      "yearProduced",
      "summary"
    ],
    "enhancedFields": 4,
    "contentLength": 1976
  },
  "response": "{\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Guideline for Carbetocin Use to Prevent Postpartum Hemorrhage in Cesarean Birth\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"RCOG\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The text does not contain a publication year\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Carbetocin Guideline for Postpartum Haemorrhage Prevention in Caesarean Birth** **Purpose**: Carbetocin is recommended to prevent postpartum haemorrhage during caesarean birth, replacing oxytocin (not used alongside it). **Administration**: - Give **100 mcg over 1 minute** after baby’s birth and cord clamping. - Avoid pre-birth administration. - Consider dose reduction for low-risk elective cases; never exceed 100 mcg. **Roles**: - **Anaesthetist**: Prepares, administers, and documents. - **Obstetrician**: Manages 3rd stage, monitors uterine tone. - **Midwife**: Monitors tone/lochia, escalates concerns. - **Theatre team**: Maintains stock. **Contraindications**: Pregnancy before birth, hypersensitivity, severe cardiovascular disease, severe pre-eclampsia/eclampsia. **Cautions**: Cardiovascular disease (avoid if severe), hypotension, hyponatraemia, pre-eclampsia, general anaesthesia. **Adverse Effects**: Headache, nausea, hypotension, flushing, dyspnea, pruritis. **Monitoring**: Guideline compliance and incident reviews. **References**: BNF, SPC Carbetocin, NHS Injectable Medicines Guide\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "endpoint": "enhanceGuidelineMetadata",
  "timestamp": "2025-06-18T18-40-36",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"guidelineId\": \"carbetocin-to-prevent-pph-at-cs-uhs-cg-0009-2023-pdf\",\n  \"fieldsProcessed\": [\n    \"humanFriendlyName\",\n    \"organisation\",\n    \"yearProduced\",\n    \"summary\"\n  ],\n  \"enhancedFields\": 4,\n  \"contentLength\": 1976\n}\n\nA: {\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Guideline for Carbetocin Use to Prevent Postpartum Hemorrhage in Cesarean Birth\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"RCOG\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The text does not contain a publication year\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Carbetocin Guideline for Postpartum Haemorrhage Prevention in Caesarean Birth** **Purpose**: Carbetocin is recommended to prevent postpartum haemorrhage during caesarean birth, replacing oxytocin (not used alongside it). **Administration**: - Give **100 mcg over 1 minute** after baby’s birth and cord clamping. - Avoid pre-birth administration. - Consider dose reduction for low-risk elective cases; never exceed 100 mcg. **Roles**: - **Anaesthetist**: Prepares, administers, and documents. - **Obstetrician**: Manages 3rd stage, monitors uterine tone. - **Midwife**: Monitors tone/lochia, escalates concerns. - **Theatre team**: Maintains stock. **Contraindications**: Pregnancy before birth, hypersensitivity, severe cardiovascular disease, severe pre-eclampsia/eclampsia. **Cautions**: Cardiovascular disease (avoid if severe), hypotension, hyponatraemia, pre-eclampsia, general anaesthesia. **Adverse Effects**: Headache, nausea, hypotension, flushing, dyspnea, pruritis. **Monitoring**: Guideline compliance and incident reviews. **References**: BNF, SPC Carbetocin, NHS Injectable Medicines Guide\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": null
}